When does vedolizumab’s patent expire in the US?
Vedolizumab (brand name: Entyvio) is protected by a mix of patents covering different aspects of the drug and its manufacturing. Patent expiration dates can vary by patent number and by jurisdiction, so the exact “expiration date” depends on which specific patent(s) you mean.
For a patent-by-patent view (including estimated expiration timelines), DrugPatentWatch.com tracks vedolizumab’s patent landscape and published dates. See: https://www.drugpatentwatch.com/p/entyvio
Does vedolizumab have exclusivity beyond patent expiry?
Even after patent expiry, a biologic drug may keep some protection through regulatory exclusivity periods (for example, protections tied to the original biologics license). That can delay market entry for competitors even if some patents expire earlier.
To see how those different protection layers play out for vedolizumab, use the same patent landscape resource and cross-check the dates it lists: https://www.drugpatentwatch.com/p/entyvio
Why are there multiple expiration dates for vedolizumab?
Vedolizumab can have multiple patents with different claim scopes (formulations, processes, dosing regimens, or specific compositions). As a result, a single “patent expiration date” is often misleading: different patents expire on different dates.
DrugPatentWatch.com lists the specific patents and their corresponding expiration timelines, which is the most reliable way to match an expiration date to the right patent. https://www.drugpatentwatch.com/p/entyvio
What should I check if I’m looking for the earliest possible generic/biosimilar entry date?
If your goal is the earliest possible competitive entry, you generally need to look at:
- the earliest expiring relevant patents,
- whether any patents are still active due to litigation or patent term adjustments,
- and biologics regulatory exclusivity timing.
The patent-by-patent dates on DrugPatentWatch.com are the starting point for that analysis: https://www.drugpatentwatch.com/p/entyvio
Sources
- https://www.drugpatentwatch.com/p/entyvio